Detalles de la búsqueda
1.
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies.
Blood
; 142(6): 553-560, 2023 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37257195
2.
The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
Breast Cancer Res
; 25(1): 32, 2023 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36978142
3.
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Lancet Oncol
; 22(8): 1151-1161, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34252375
4.
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Int J Cancer
; 148(10): 2614-2627, 2021 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33533487
5.
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Cancer
; 126(22): 4847-4858, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32780421
6.
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Int J Cancer
; 145(3): 857-868, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30694523
7.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 175(1): 265-266, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30632020
8.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 165(3): 573-583, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28664507
9.
Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69).
Breast Cancer Res Treat
; 163(3): 495-506, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28315068
10.
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
Lancet Oncol
; 17(3): 345-356, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26869049
11.
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Leukemia
; 38(1): 160-167, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37845285
12.
Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.
Eur J Cancer
; 194: 113324, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37797387
13.
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.
Clin Cancer Res
; 29(22): 4606-4612, 2023 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37725572
14.
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
JAMA Oncol
; 9(7): 946-954, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37166817
15.
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
J Clin Oncol
; 41(22): 3796-3804, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36809046
16.
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
Breast Cancer Res Treat
; 132(3): 863-70, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21667238
17.
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
JAMA Oncol
; 8(7): 1010-1018, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35588050
18.
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
Breast Cancer Res Treat
; 123(2): 437-45, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20623180
19.
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
J Clin Oncol
; 37(25): 2226-2234, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31082269
20.
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
J Clin Oncol
; 34(20): 2341-9, 2016 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26926676